Basket | Login | Register


WP2: Development and validation of translatable provocation challenges (Pre-clinical studies)

Work Packages

Pharmacog Logo

Main Objectives

  • To develop validated pre-clinical challenge models with increased predictive capacity to support ranking of novel drugs.
  • To further test the reproducibility and sensitivity of novel biomarkers that can be used for PK/PD studies.
  • To establish mathematical models describing the relationship between drug exposure and biomarker response and the relationship between pre-clinical and clinical studies.

WP Leads

Academic Lead: Dr Fabienne Aujard (CNRS, France)

Industry Lead: Dr Yves Lamberty (UCB)

WP Partners

  • University of Lille, France
  • University of Murcia, Spain
  • CNRS, France
  • University of Verona, Italy
  • University of Foggia, Italy
  • Mario Negri Institute, Italy
  • GSK
  • Servier
  • UCB
  • Lilly
  • J&J



Last Updated: Monday 18 October 2010


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations